Cardiac β-adrenoceptor expression is reduced in Zucker diabetic fatty rats as type-2 diabetes progresses

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Haley, James M ^a,b   Thackeray, James T ^a,b,d   Thorn, Stephanie L ^a,b,e   DaSilva, Jean N ^a,b,c  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; FATTY ACID; GLUCOSE; INSULIN; LEPTIN; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; DISEASE COURSE; ECHOCARDIOGRAPHY; EX VIVO STUDY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; WESTERN BLOTTING; ANIMAL; BLOOD; CARDIAC MUSCLE; COMPLICATION; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HEART DISEASES; METABOLISM; PATHOPHYSIOLOGY; ZUCKER RAT;

RATTUS;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; FATTY ACIDS, NONESTERIFIED; GENE EXPRESSION REGULATION; HEART DISEASES; HYPERGLYCEMIA; INSULIN; LEPTIN; MALE; MYOCARDIUM; RATS; RATS, ZUCKER; RECEPTORS, ADRENERGIC, BETA;

EID: 84930669136     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127581     Document Type: Article

References (43)

1. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nat Rev Endocrinol. 2011; 8: 228-236. doi: 10.1038/nrendo.2011.183 PMID: 22064493
2. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002; 25: 1129-1134. PMID: 12087009
3. From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol. 2010; 55: 300-305. doi: 10.1016/j.jacc.2009.12.003 PMID: 20117433
4. Chareonthaitawee P, Sorajja P, Rajagopalan N, Miller TD, Hodge DO, Frye RL, et al. Prevalence and prognosis of left ventricular systolic dysfunction in asymptomatic diabetic patients without known coronary artery disease referred for stress single-photon emission computed tomography and assessment of left ventricular function. Am Heart J. 2007; 154: 567-574. PMID: 17719308
5. Falcao-Pires I, Leite-Moreira AF. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev. 2012; 17: 325-344. doi: 10.1007/s10741-011-9257-z PMID: 21626163
6. Straznicky NE, Grima MT, Sari CI, Eikelis N, Lambert EA, Nestel PJ, et al. Neuroadrenergic dysfunction along the diabetes continuum: a comparative study in obese metabolic syndrome subjects. Diabetes. 2012; 61: 2506-2516. PMID: 22664956
7. Straznicky NE, Grima MT, Sari CI, Karapanagiotidis S, Wong C, Eikelis N. The relation of glucose metabolism to left ventricular mass and function and sympathetic nervous system activity in obese subjects with metabolic syndrome. J Clin Endocrinol Metab. 2013; 98: E227-237. doi: 10.1210/jc.2012-3277 PMID: 23271752
8. Ren J. Leptin and hyperleptinemia - from friend to foe for cardiovascular function. J Endocrinol. 2004; 181: 1-10. PMID: 15072562
9. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010; 55: 2212-2221. doi: 10.1016/j.jacc.2010.01.014 PMID: 20188504
10. Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res. 2013; 113: 739-753. doi: 10.1161/CIRCRESAHA.113.300308 PMID: 23989716
11. Thackeray JT, deKemp RA, Beanlands RS, DaSilva JN. Insulin restores myocardial presynaptic sympathetic neuronal integrity in insulin-resistant diabetic rats. J Nucl Cardiol. 2013; 20: 845-856. doi: 10.1007/s12350-013-9759-2 PMID: 23842711
12. Naya M, Tsukamoto T, Morita K, Katoh C, Nishijima K, Komatsu H, et al. Myocardial beta-adrenergic receptor density assessed by 11C-CGP12177 PET predicts improvement of cardiac function after carvedilol treatment in patients with idiopathic dilated cardiomyopathy. J Nucl Med. 2009; 50: 220-225. doi: 10.2967/jnumed.108.056341 PMID: 19164238
13. Dincer UD, Bidasee KR, Guner S, Tay A, Ozcelikay AT, Altan VM. The effect of diabetes on expression of beta1-, beta2-, and beta3-adrenoreceptors in rat hearts. Diabetes. 2001; 50: 455-461. PMID: 11272160
14. Matsuda N, Hattori Y, Gando S, Akaishi Y, Kemmotsu O, Kanno M. Diabetes-induced down-regulation of beta1-adrenoceptor mRNA expression in rat heart. Biochem Pharmacol. 1999; 58: 881-885. PMID: 10449200
15. Thackeray JT, Parsa-Nezhad M, Kenk M, Thorn SL, Kolajova M, Beanlands RS, et al. Reduced CGP12177 binding to cardiac beta-adrenoceptors in hyperglycemic high-fat-diet-fed, streptozotocin-induced diabetic rats. Nucl Med Biol. 2011; 38: 1059-1066. doi: 10.1016/j.nucmedbio.2011.04.002 PMID: 21831645
16. Bugger H, Abel ED. Rodent models of diabetic cardiomyopathy. Dis Model Mech. 2009; 2: 454-466. doi: 10.1242/dmm.001941 PMID: 19726805
17. Etgen GJ, Oldham BA. Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state. Metabolism. 2000; 49: 684-688. PMID: 10831184
18. Van Waarde A, Meeder JG, Blanksma PK, Brodde OE, Visser GM, Elsinga PH, et al. Uptake of radioligands by rat heart and lung in vivo: CGP 12177 does and CGP 26505 does not reflect binding to beta-adrenoceptors. Eur J Pharmacol. 1992; 222: 107-112. PMID: 1361437
19. Haddad C, Wilkinson M, Roeder LM, Tildon JT, Armour JA. Binding of the hydrophilic beta-adrenergic antagonist [3H]CGP-12177 to cardiac tissue slices: characterization and ontogenetic studies in dogs. Can J Physiol Pharmacol. 1987; 65: 1928-1933. PMID: 2891424
20. van den Brom CE, Huisman MC, Vlasblom R, Boontje NM, Duijst S, Lubberink M, et al. Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats: studies using positron emission tomography. Cardiovasc Diabetol. 2009; 8: 39. doi: 10.1186/1475-2840-8-39 PMID: 19624828
21. Grueneberger JM, Fritz T, Zhou C, Meyer S, Karcz-Socha I, Sawczyn T, et al. Long segment ileal transposition leads to early amelioration of glucose control in the diabetic obese Zucker rat. Wideochir Inne Tech Malo Inwazyjne. 2013; 8: 130-138. doi: 10.5114/wiitm.2011.32925 PMID: 23837097
22. Oltman CL, Davidson EP, Coppey LJ, Kleinschmidt TL, Yorek MA. Treatment of Zucker diabetic fatty rats with AVE7688 improves vascular and neural dysfunction. Diabetes Obes Metab. 2009; 11: 223-233. doi: 10.1111/j.1463-1326.2008.00924.x PMID: 18564175
23. Huang L, Wang Z, Li C. Modulation of circulating leptin levels by its soluble receptor. J Biol Chem. 2001; 276: 6343-6349. PMID: 11102451
24. Sarkozy M, Zvara A, Gyemant N, Fekete V, Kocsis GF, Pipis J, et al. Metabolic syndrome influences cardiac gene expression pattern at the transcript level in male ZDF rats. Cardiovasc Diabetol. 2013; 12: 16. doi: 10.1186/1475-2840-12-16 PMID: 23320804
25. Paolillo S, Rengo G, Pagano G, Pellegrino T, Savarese G, Femminella GD, et al. Impact of diabetes on cardiac sympathetic innervation in patients with heart failure: a 123I meta-iodobenzylguanidine (123I MIBG) scintigraphic study. Diabetes Care. 2013; 36: 2395-2401. doi: 10.2337/dc12-2147 PMID: 23530014
26. Carmena R. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance. Am Heart J. 2005; 150: 859-870. PMID: 16290951
27. Marsh SA, Powell PC, Agarwal A, Dell'Italia LJ, Chatham JC. Cardiovascular dysfunction in Zucker obese and Zucker diabetic fatty rats: role of hydronephrosis. Am J Physiol Heart Circ Physiol. 2007; 293: H292-298. PMID: 17351065
28. DCCT. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia. 1998; 41: 416-423. PMID: 9562345
29. Azad N, Emanuele NV, Abraira C, Henderson WG, Colwell J, Levin SR, et al. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). J Diabetes Complications. 1999; 13: 307-313. PMID: 10765007
30. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348: 383-393. PMID: 12556541
31. Nemanich S, Rani S, Shoghi K. In vivo multi-tissue efficacy of peroxisome proliferator-activated receptor-gamma therapy on glucose and fatty acid metabolism in obese type 2 diabetic rats. Obesity (Silver Spring). 2013; 21: 2522-2529. doi: 10.1002/oby.20378 PMID: 23512563
32. Muzzin P, Revelli JP, Fraser CM, Giacobino JP. Radioligand binding studies of the atypical beta 3-adrenergic receptor in rat brown adipose tissue using [3H]CGP 12177. FEBS Lett. 1992; 298: 162-164. PMID: 1347503
33. Puigserver P, Pico C, Stock MJ, Palou A. Effect of selective beta-adrenoceptor stimulation on UCP synthesis in primary cultures of brown adipocytes. Mol Cell Endocrinol. 1996; 117: 7-16. PMID: 8734469
34. van Waarde A, Anthonio RL, Visser TJ, Elsinga PH, Posthumus H, Weemaes AM, et al. Quantification of an 11C-labelled β-adrenoceptor ligand, S-(-)CGP12177, in plasma of humans and rats. J Chromatogr B Biomed Appl. 1995; 663: 361-369. PMID: 7735484
35. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation. 1986; 74: 1290-1302. PMID: 3022962
36. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, et al. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest. 1992; 89: 803-815. PMID: 1311717
37. Nikolaev VO, Moshkov A, Lyon AR, Miragoli M, Novak P, Paur H, et al. β2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science. 2010; 327: 1653-1657. doi: 10.1126/science.1185988 PMID: 20185685
38. Timofeyev V, Myers RE, Kim HJ, Woltz RL, Sirish P, Heiserman JP, et al. Adenylyl cyclase subtype-specific compartmentalization: Differential regulation of L-type Ca2+ current in ventricular myocytes. Circ Res. 2013; 112: 1567-1576. doi: 10.1161/CIRCRESAHA.112.300370 PMID: 23609114
39. Rozec B, Erfanian M, Laurent K, Trochu JN, Gauthier C. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. J Am Coll Cardiol. 2009; 53: 1532-1538. doi: 10.1016/j.jacc.2008.11.057 PMID: 19389564
40. Toblli J, Cao G, Rivas C, Munoz M, Giani J, Dominici F, et al. Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats. J Hypertens. 2010; 28: 1007-1019. PMID: 20411618
41. Daniels A, Linz D, van Bilsen M, Rutten H, Sadowski T, Ruf S, et al. Long-term severe diabetes only leads to mild cardiac diastolic dysfunction in Zucker diabetic fatty rats. Eur J Heart Fail. 2012; 14: 193-201. doi: 10.1093/eurjhf/hfr166 PMID: 22253456
42. Fredersdorf S, Thumann C, Ulucan C, Griese DP, Luchner A, Riegger GA, et al. Myocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty rats. Cardiovasc Pathol. 2004; 13: 11-19. PMID: 14761780
43. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA. 2009; 301: 1547-1555. doi: 10.1001/jama.2009.476 PMID: 19366774